Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet

SHANGHAI, Sept. 3, 2018 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized controlled trial...

from PR Newswire: //https://ift.tt/2LOpYT7